Viela Bio Gears Up For IPO
Viela Bio filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its IPO. The company intends to price 7.5 million shares in the range of $19 to $21, with…
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 86
Why Parkinson’s Patients Should Be Optimistic About Acadia’s Study
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with depressive symptoms.
Major Biotechs Scare Off Short Sellers
The September 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Why This Late-Stage Narcolepsy Study Is Way Ahead of Schedule
Avadel Pharma shares jumped on Monday morning after the firm announced that the FDA has agreed to the company’s proposed amendments to a statistical analysis plan and protocol.
7 Biotechs With Catalysts in the Next Month
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
Protect Your Dogs and Cats From These Fall Poisons
Most dog and cat owners know they shouldn’t feed their pets things like chocolate, nuts, and salty snack foods, and may be aware that plants like tulips and azaleas can be toxic to the…
Is This Epilepsy Cannabinoid Treatment Really in Trouble?
Zynerba Pharmaceuticals has announced positive results from its midstage epilepsy trial, and yet its shares dropped on Wednesday.
Will This Ebola Vaccine Be the Next Big Thing?
NewLink Genetics shares jumped on Wednesday after the firm announced that the FDA has accepted Merck’s Biologics License Application and granted priority review for the investigational Ebola vaccine.
Even More Implied Analyst Upside for Karyopharm Therapeutics After Royalty Pact
Karyopharm rose sharply on news of a royalty agreement that could bring as much as $150 million in new capital to the company, and one analyst sees much higher upside on the heels of…
Good News, Bad News in the War on Peanut Allergy
Aimmune shares dipped on Monday after the FDA's Allergenic Products Advisory Committee voted to support the use of AR101 (Palforzia) in children and teens with peanut allergy.
Are Alder Shareholders Getting Enough in the Buyout?
Alder Bio shares skyrocketed on Monday after the firm announced that Lundbeck would be acquiring it. The transaction is valued at up to $1.95 billion and is expected to close in the fourth quarter…
How Old Is Too Old to Be President? Medical Experts Weigh In
As the current pack of Democratic candidates has several candidates who are over 70 years old, and President Donald Trump is 73, some experts have addressed the question of how old is too old…
New Study Finds Dangerous Plastics in Children’s Bodies
Studies have found that microplastics are in the human food chain. Perhaps most disturbing is one that shows they have been discovered in blood and urine samples of young children.
7 Biotechs With Catalysts in the Next Month
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
FDA Gets Off the Pot for IBS Treatment Approval
Ardelyx shares dropped on Friday after the firm announced that the FDA has approved its treatment of irritable bowel syndrome with constipation in adults.